Nitazoxanide: profile and news

Tampa Firm's Medication Has Enormous Potential As Hepatitis ...  Feb 24, 2006
...even. For nitazoxanide, the compound that lies at the heart of the excitement, this is just the latest twist in a strange history. ... - International News Service,

Romark to Develop Alinia (nitazoxanide) as New Treatment for ...  Jan 10, 2006
10, 2006 /PRNewswire/ -- Romark Laboratories announced that it is initiating US clinical development of Alinia(R) (nitazoxanide) tablets for treating chronic ... - PharmaLive.com (press release),

Romark Laboratories to Develop Alinia as New Treatment for Chronic ...  Jan 10, 2006
TAMPA, Fla. -- Romark Laboratories announced that it is initiating US clinical development of Alinia (nitazoxanide) tablets for treating chronic hepatitis C. ... - EndoNurse,

(PRN) - CYIOS Corporation Announces Record Quarterly and Annual ...  Jan 10, 2006
Awards ... [+. PRN) - Romark to Develop Alinia(R) (nitazoxanide) as New Treatment for Chronic Hepatitis C ... [+. PRN) - Spartan ... - Bolsamania.com,

Romark Advances Development of Alinia in Treating Clostridium ...  Dec 8, 2005
8 /PRNewswire/ -- Romark Laboratories announced another advance in its development of Alinia (nitazoxanide) for treating Clostridium difficile-associated ... - PR Newswire (press release),

Romark Advances Development of Alinia in Treating Clostridium ...  Dec 8, 2005
TAMPA, Fla., December 08, 2005 /PRNewswire/ -- Romark Laboratories announced another advance in its development of Alinia (nitazoxanide) for treating ... - PharmaLive.com (press release),

Development of Alinia in Treating Clostridium Difficile-Associated ...  Dec 8, 2005
...-- Romark Laboratories announced another advance in its development of Alinia (nitazoxanide) for treating Clostridium difficile-associated disease (CDAD). ... - EndoNurse,

Romark Completes Clinical Study of Alinia in Treating Clostridium ...  Nov 18, 2005
Romark Laboratories announced completion of a prospective, randomized, double-blind clinical trial comparing Alinia (nitazoxanide) to metronidazole (standard ... - PR Newswire (press release),

AAEP Wrap-Up: Neurologic Disease/WNV  Oct 25, 2005
Another drug--Navigator, sold by IDEXX--had just received FDA approval for the treatment of EPM. The active ingredient is nitazoxanide. ... - TheHorse.com,

Romark Laboratories to Distribute Alinia to Public Health ...  08 Sep 2005
Romark Laboratories announced today it will donate up to $1 million of its gastrointestinal anti-infective drug, Alinia (nitazoxanide), to public health ... - PR Newswire (press release),

Romark Labs donates $1 million in drugs for Gulf states  08 Sep 2005
...gastrointestinal infections. Romark Laboratories said it would donate up to $1 million of the drug, Alinia (nitazoxanide). The drug ... - Tampa Bay Business Journal,

Use of Nitazoxanide As a New Therapeutic Option for Persistent ...  Aug 12, 2005
This article discusses the empiric use of anti-infective nitazoxanide, a thiazolide compound, in three case reports of children with persistent diarrhea, and ... - RedNova.com,

Ind Swift gets DCGI nod for anti-diarrhoeal drug  Aug 22, 2005
...bacterial drug. The drug is a combination of 500 mg Nitazoxanide (anti-diarrhea agent) plus 200 mg Oflxacin (quinoline derivative). The ... - India Infoline.com,

Romark Laboratories Announces Clinical Study Evaluating Alinia(R) ...  Aug 24, 2005
24 /PRNewswire/ -- Romark Laboratories has begun enrolling patients in a clinical trial evaluating Alinia (nitazoxanide) for treatment of mild to moderate ... - PR Newswire (press release),

Romark Laboratories Announces Clinical Study Evaluating Alinia for ...  Aug 24, 2005
Fla., August 24, 2005 /PRNewswire/ -- Romark Laboratories has begun enrolling patients in a clinical trial evaluating Alinia (nitazoxanide) for treatment of ... - PharmaLive.com (press release),

New Drug Study Underway For Chron's Disease  Aug 28, 2005
Romark Laboratories has begun enrolling patients in a clinical trial evaluating Alinia (nitazoxanide) for treatment of mild to moderate active Crohn's disease ... - All Headline News

Ind-Swift gets DCGI approval  Aug 24, 2005
The combination drug developed by the company, comprises 500 mg Nitazoxanide plus 200 mg Oflxacin and is an effective cure for a number of infections like skin ... - Economic Times,

Romark Laboratories to begin study into Crohn's disease  Aug 25, 2005
The study will be conducted in multiple centers in the United States. "We believe nitazoxanide (Alinia) presents a unique and innovative approach to treating ... - Pharmaceutical Business Review

Ind Swift gets DCGI nod for new drug  Aug 23, 2005
Swift said. The drug is a combination of 500 mg Nitazoxanide (anti-diarrhoea agent) plus 200 mg Oflxacin (quinoline derivative). The ... - Sify,

EPM Today  Aug 22, 2005
...the future.". Currently, two new drug compounds are awaiting FDA approval--diclazuril and nitazoxanide (NTZ). "The effectiveness ... - TheHorse.com,

Cryptosporidiosis at New York Water Park Sickens a Baker's Dozen  Aug 22, 2005
The most common treatment for cryptosporidium infection is the drug Alinia (nitazoxanide), an antiparasitic drug that treats diarrhea caused by the organism. ... - MedPage Today,

EPM Update  Aug 19, 2005
On yet another front, nitazoxanide (NTZ), an anti-protozoal drug developed in human medicine, also is under investigation as a possible treatment for EPM. ... - TheHorse.com,

Ind-Swift gets DCGI approval for anti-diarrhoeal drug  Jul 22, 2005
Swift. The drug is a combination of 500 mg Nitazoxanide (anti-diarrhoeal agent) plus 200 mg Oflxacin (quinoline derivative). “The ... - Express Pharma Pulse

Cryptosporidiosis Presenting As Acute Appendicitis: A Case Report  Jul 8, 2005
Treatment for symptomatic patients usually involves a combination therapy of an antimicrobial (nitazoxanide, paromomycin, azithromycin) and an antidiarrheal ... - RedNova.com

Ind-Swift receives a DCGI approval for its anti-diarrhoeal drug  Jul 14, 2005
...manufactures active pharmaceutical ingredients and advanced intermediates, already has a drug in this segment that is widely known by the name Nitazoxanide. ... - Express Pharma Pulse <**results**>

Cryptosporidiosis Presenting As Acute Appendicitis: A Case Report  Jul 8, 2005
Treatment for symptomatic patients usually involves a combination therapy of an antimicrobial (nitazoxanide, paromomycin, azithromycin) and an antidiarrheal ... - RedNova.com

FDA Approvals: Revatio, Xeloda, Alinia  Jun 23, 2005
...tablets for adjuvant use in the treatment of patients with Dukes' C colon cancer when fluoropyrimidine monotherapy is preferred, and nitazoxanide tablets and ... - Medscape (subscription)

Alinia Approved by FDA to Treat Cryptosporidium in Adults  Jun 27, 2005
Tampa, Fla., infozine - The US Food and Drug Administration (FDA) has approved Alinia® (nitazoxanide) tablets and oral suspension for treating diarrhea caused ... - Kansas City infoZine

FDA approves treatment for diarrhea caused by Cryptosporidium ...  Jun 19, 2005
The US Food and Drug Administration (FDA) has approved Alinia (nitazoxanide) tablets and oral suspension for treating diarrhea caused by Cryptosporidium parvum ... - News-Medical.net

FDA Approves First-Ever Treatment for Adults, Teens with Diarrhea ...  Jun 16, 2005
TAMPA, Fla. — The US Food and Drug Administration (FDA) has approved Alinia(R) (nitazoxanide) tablets and oral suspension for treating diarrhea caused by ... - Drug Newswire (press release)

FDA Approves First-Ever Treatment for Adults, Teens with Diarrhea ...  Jun 16, 2005
TAMPA, Fla., June 16, 2005 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved Alinia(R) (nitazoxanide) tablets and oral suspension for ... - PharmaLive.com (press release)

FDA approves diarrhea drug  Jun 17, 2005
In a recent study of patients with diarrhea caused by Cryptosporidium, Alinia (nitazoxanide) significantly reduced the duration of diarrhea and other ... - Pharmaceutical Business Review

Tizoxanide is highly bound to plasma protein (>99.9%). Therefore, caution should be used when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin). In vitro metabolism studies have demonstrated that tizoxanide has no significant inhibitory effect on cytochrome P450 enzymes. Although no drug-drug interaction studies have been conducted in vivo, it is expected that no significant interaction would occur when nitazoxanide is co-administered with drugs that either are metabolized by or inhibit cytochrome P450 enzymes.